[1] 姚新飞,许素清,谢麒麟. 不同输注方法对英夫利西单抗不良反应的影响[J]. 护理学杂志,2013,28(8):17-19. [2] Fukuyo S, Saito K, Yamaoka K, et al. Efficacy and safety of reducing duration of infliximab infusion[J]. Mod Rheumatol, 2014,24(2):275-280. [3] 陈国强,郭冬梅,张红卫,等.英夫利西单抗注射安全性的临床观察[J].实用医学杂志,2010,26(13):2415-2416. [4] Tyler L N, Harville T O, Blackall D P. Multiple alloantibodies after transfusion in an infant treated with infliximab[J]. N Engl J Med,2007,357(20): 2092-2093; [5] Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgEantibodies and induction of infusion-related severe anaphylactic reactions[J]. Allergy,2010,65(5):657-661. [6] 杨世春.临床输液反应相关因素探讨及预防[J].中国医药指南,2011,9(20):299-300. [7] Dixon W G, Hyrich K L, Watson K D, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)[J]. Ann Rheum Dis,2010,69(3):522–528. [8] Navarra S V, Tang B, Lu L, et al. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia[J]. Int J Rheum Dis,2014,17(3):291-298. [9] Solovic I, Sester M, Gomez-Reino J J, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement[J]. Eur Respir J,2010,36(5): 1185-1206. [10] 中华医学会皮肤性病分会银屑病学组. 中国银屑病治疗专家共识(2014版)[J]. 中华皮肤科杂志,2014,47(3):213-215. [11] 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识[J].中华风湿病学杂志,2013,17(8):508-512. [12] Bjrnsson E S, Gunnarsson B I, Grndal G, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists[J]. Clin Gastroenterol Hepatol,2015,13(3): 602-608. [13] Rossi R E, Parisi I, Despott E J, et al. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management[J]. World J Gastroenterol,2014,20(46):17352-17359. [14] Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis[J]. Gut,2004,53(9):1363–1365. [15] Castro K R, Aikawa N E, Saad C G, et al. Infliximab induces increase in triglyceride levels in psoriatic arthritis patients[J]. Clin DevImmunol,2011,2011(2):352686. [16] Koutroubakis I E, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease[J].Eur J Gastroenterol Hepatol,2009,21(3):283–288. [17] 方霖楷,潘云峰,黄建林,等. 类风湿关节炎伴 HBV 携带患者接受英夫利昔单抗治疗的肝脏安全性观察[J]. 风湿病与关节炎,2014,3(2):27-29. [18] Phelan C, Wooltorton E. Infliximab and serious hematologic events[J].CMAJ,2004, 171(9):1045. [19] 胡扬,王兰,张波,等. 英夫利西单抗诱发再生障碍性贫血[J]药物不良反应杂志,2012,14(6):382-384. [20] Mocciaro F, Russo G, Di Mitri R, et al. Infliximab-induced thrombocytopenia in an elderly patient with ileocolonic Crohn’s disease[J]. Inflamm Bowel Dis,2013, 19(4):E52-E53. |